Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

30 Jun 2011 13:18

RNS Number : 4784J
Omega Diagnostics Group PLC
30 June 2011
 



30 June 2011 AIM: ODX

 

Omega Diagnostics Group PLC

("Omega" or "the Company")

 

Directorate Change

 

Omega, the AIM listed medical diagnostics company, announces that Jag Grewal will join the Board as an Executive Director with immediate effect.

 

Jag Grewal, aged 42, joined the Company on 6 June 2011 as Group Sales and Marketing Director. Jag has worked in diagnostics for over 20 years having started out as a Clinical Biochemist in the NHS. In 1995, he joined Beckman Instruments where he developed a career spanning 15 years in sales and marketing holding a variety of positions in sales, product management and marketing management.

 

In 2009, Jag left as Northern Europe Marketing Manager to join Serco Health where he helped create the first joint venture within UK pathology between Serco Health and Guys and St Thomas' Hospital NHS Foundation Trust. Jag is also past Chairman and current treasurer of the British In-Vitro Diagnostics Association (BIVDA).

 

Andrew Shepherd, the Company's Chief Executive said: "We are very pleased to welcome Jag to the Board and his wealth of experience will be beneficial as we expand the scale of the Group's sales and marketing function in line with our expansion plans."

 

 

For further enquiries please contact:

 

Omega Diagnostics Group PLC

Tel: 01259 763 030

Andrew Shepherd, Chief Executive

Kieron Harbinson, Group Finance Director

www.omegadiagnostics.com

Cenkos Securities plc

Tel: 020 7397 8900

Ian Soanes

Elizabeth Bowman

Walbrook PR Limited

Paul McManus

Tel: 020 7933 8787

Mob: 07980 541 893

paul.mcmanus@walbrookpr.com

Fiona Henson

Tel: 020 7933 8795

Mob: 07886 335 992

fiona.henson@walbrookpr.com

 

 

 

Additional information:

 

Jag Grewal, aged 42, holds no shares in the Company and other than as set out below, there is no further information to be disclosed under schedule 2(g) and Rule 17 of the AIM Rules in respect of Mr Grewal's appointment today as a Director of the Company.

 

Mr Grewal is a director / partner or has been a director / partner of the following companies / partnerships during the previous five years:

 

British In-Vitro Diagnostics Association

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAWGUQGQUPGGPU
Date   Source Headline
22nd May 202012:30 pmRNSExercise of Options and TVR
15th May 202011:05 amRNSSecond Price Monitoring Extn
15th May 202011:00 amRNSPrice Monitoring Extension
13th May 20202:00 pmRNSPrice Monitoring Extension
7th May 20208:15 amRNSExercise of Options and TVR
6th May 202011:00 amRNSPrice Monitoring Extension
4th May 202011:00 amRNSExercise of Options and TVR
1st May 20202:30 pmRNSHolding(s) in Company
1st May 20202:05 pmRNSSecond Price Monitoring Extn
1st May 20202:00 pmRNSPrice Monitoring Extension
30th Apr 202012:00 pmRNSExercise of Options and TVR
29th Apr 20205:37 pmRNSHolding(s) in Company
29th Apr 20207:00 amRNSHolding(s) in Company
28th Apr 20205:43 pmRNSHolding(s) in Company
28th Apr 20207:00 amRNSVISITECT® CD4 Advanced Disease - supply agreement
27th Apr 20204:42 pmRNSSecond Price Monitoring Extn
27th Apr 20204:36 pmRNSPrice Monitoring Extension
27th Apr 20209:06 amRNSSecond Price Monitoring Extn
27th Apr 20209:00 amRNSPrice Monitoring Extension
27th Apr 20207:00 amRNSCE-Mark of COVID-19 ELISA antibody test
24th Apr 202011:00 amRNSPrice Monitoring Extension
20th Apr 20202:05 pmRNSSecond Price Monitoring Extn
20th Apr 20202:00 pmRNSPrice Monitoring Extension
20th Apr 20201:24 pmRNSHolding(s) in Company
20th Apr 20201:23 pmRNSHolding(s) in Company
20th Apr 20207:00 amRNSHolding(s) in Company
20th Apr 20207:00 amRNSCOVID-19 MTA signed with Mologic Ltd
16th Apr 20205:40 pmRNSHolding(s) in Company
16th Apr 20207:00 amRNSHolding(s) in Company
14th Apr 20203:06 pmRNSHolding(s) in Company
9th Apr 20204:41 pmRNSSecond Price Monitoring Extn
9th Apr 20204:36 pmRNSPrice Monitoring Extension
9th Apr 20207:00 amRNSCOVID-19 Consortium MOU
6th Apr 20209:30 amRNSVISITECT® CD4 Advanced Disease evaluation
6th Apr 20208:34 amRNSHolding(s) in Company
2nd Apr 20207:00 amRNSChinese Approval for Food Detective® test
2nd Apr 20207:00 amRNSTrading Update
24th Jan 20207:00 amRNSGrant of Options under Company EMI Plan
21st Jan 20203:24 pmRNSHolding(s) in Company
20th Jan 20207:00 amRNSExercise of Options and Total Voting Rights
17th Jan 202010:30 amRNSNigerian MOH approval for VISITECT CD4 350 test
8th Jan 202012:13 pmRNSHolding(s) in Company
16th Dec 20194:05 pmRNSDirector/PDMR Shareholding
9th Dec 20194:30 pmRNSHolding(s) in Company
2nd Dec 20199:00 amRNSGrant of Share Options
2nd Dec 20197:00 amRNSInterim Results
2nd Dec 20197:00 amRNSNigerian order for VISITECT® CD4
25th Nov 20197:00 amRNSUpdate on Allergy test menu
21st Nov 20197:00 amRNSInvestor results briefing
22nd Oct 201911:39 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.